Rapid dose escalation, lack of nutritional guidance, poor hydration, and limited symptom monitoring all increase risk
At the moment, the regulatory agency is reviewing a decision it rendered earlier this month to remove Eli Lillys diabetes blockbuster Mounjaro and its popular obesity medication Zepbound both GLP-1 medications from the national shortage list
Changes in Vision: If you have type 2 diabetes and notice changes in your vision while taking Zepbound, inform your healthcare provider
In light of these findings, which were published in November, the FDAs decision to approve the drug for preventing heart problems wasnt surprising at all, says Joseph Wu, a cardiologist at Stanford University
LifeMDs Integrated Virtual Weight Management Program LifeMDs weight management program provides personalized, clinically guided care for patients across the U.S